Latest news with #PolyMedicure
&w=3840&q=100)
Business Standard
07-05-2025
- Business
- Business Standard
Poly Medicure Q4 results: Profit rises 34% on strong exports, new divisions
Delhi-based medical device manufacturer Poly Medicure on Wednesday announced a 34 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) for the March quarter of financial year 2024–25 (Q4FY25), driven by strong export revenue and the commercialisation of its new cardiology and critical care divisions. The company's PAT for the quarter was recorded at Rs 91.8 crore, up from Rs 68.4 crore in the same period last year. Its revenue from operations rose to Rs 440.8 crore in Q4FY25, a 16.6 per cent Y-o-Y rise from Rs 378.1 crore reported in Q4FY24. The company stated that its export revenue for the March quarter increased by 14 per cent year-on-year, driven by continued strong performance in key international markets. Exports formed around 67 per cent of the company's revenue mix—double that of the domestic market, which accounted for 32 per cent of overall revenue in Q4. Commenting on the performance, Himanshu Baid, managing director, Poly Medicure, said that while ongoing geopolitical conditions and uncertainty created by US-imposed tariffs may create short-term pressure on demand in certain export markets, India's Medtech sector is well positioned to benefit in the long term as global customers look to create alternate supply chains. At the operating level, Poly Medicure's earnings before interest, tax, depreciation, and amortisation (EBITDA) rose to Rs 119.5 crore, with an EBITDA margin of 27.1 per cent in the March quarter, compared to Rs 96.5 crore and 25.5 per cent, respectively, in the same period last financial year. Baid added that the company's margins have continued to expand at a higher scale of operations, giving it the confidence to continue investing capital in expanding manufacturing capacities. The company currently has 12 manufacturing facilities, with three more under construction in India. It has a portfolio of over 200 medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, among others. On Wednesday, Poly Medicure's shares rose by 2.06 per cent, closing at Rs 2,835.65 apiece on the Bombay Stock Exchange (BSE).
&w=3840&q=100)
Business Standard
07-05-2025
- Business
- Business Standard
Medical device company share price zooms 47% in 1 month. Do you own?
Poly Medicure share price today: Shares of Poly Medicure, a leading medical device company with a dominant position in India's medical consumables market, rallied 5 per cent to ₹2,922 on the BSE in Wednesday's intra-day trade after it reported a healthy financial performance for the quarter ended March 2025 (Q4FY25). The stock price of the company is trading at its highest level in calendar year 2025. It had hit a 52-week high of ₹3,350 touched on November 1, 2024. In the past one month, the stock price of Poly Medicure has zoomed 47 per cent, as compared to 2.6 per cent rise in the BSE Sensex. At 10:31 am; Poly Medicure was trading 4 per cent higher at ₹2,884.90, as against 0.11 per cent decline in the benchmark index. Poly Medicure Q4 result Revenue from operations increased by 17 per cent to ₹440.80 crore in Q4FY25 over the previous year quarter. Export revenue growth was driven by continued strong performance in key international markets. Geopolitical tensions and tariff war has created short term demand uncertainty in certain export markets, the company said. Earnings before interest, taxes, depreciation, and amortisation (Ebitda) grew by 24 per cent to ₹119.5 crore in Q4FY25 on a YoY basis, reflecting strong earnings capability from core operations. Ebitda margin has improved by 160 bps to 27 per cent in Q4FY25. Profit after tax increased by 34 per cent in Q4FY25. Management commentary The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. The management believes that the India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains. The company's investment in 3 new plants is going on strongly, which the management believes positions the company very strongly to achieve the significant growth opportunities. Crisil's view on Poly Medicure Continuous capacity addition and product innovation and development will support revenue growth over the medium term as well. Ebitda margin is expected to remain stable at 26-27 per cent over the medium term. The margin should be supported by better economies of scale, which in turn will be led by steady capacity utilisation, modernisation of facilities and cost-cutting initiatives. About Poly Medicure Poly Medicure is a leading medical device manufacturer and exporter from India, with its products sold in over 125 countries, making a significant global impact on healthcare. With a robust portfolio of over 200 medical devices and more than 300 patents, Polymed offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anaesthesia and respiratory care, urology, and surgery and wound management.
Business Standard
07-05-2025
- Business
- Business Standard
Poly Medicure consolidated net profit rises 34.33% in the March 2025 quarter
Sales rise 16.60% to Rs 440.83 croreNet profit of Poly Medicure rose 34.33% to Rs 91.83 crore in the quarter ended March 2025 as against Rs 68.36 crore during the previous quarter ended March 2024. Sales rose 16.60% to Rs 440.83 crore in the quarter ended March 2025 as against Rs 378.07 crore during the previous quarter ended March the full year,net profit rose 31.09% to Rs 338.56 crore in the year ended March 2025 as against Rs 258.26 crore during the previous year ended March 2024. Sales rose 21.37% to Rs 1669.83 crore in the year ended March 2025 as against Rs 1375.80 crore during the previous year ended March EndedYear EndedMar. 2025Mar. 2024% 2025Mar. 2024% 17 1669.831375.80 21 OPM %27.1025.51 -27.1226.00 - PBDT143.88108.54 33 535.15407.71 31 PBT122.8592.46 33 452.52344.27 31 NP91.8368.36 34 338.56258.26 31 Powered by Capital Market - Live News
Business Upturn
07-05-2025
- Business
- Business Upturn
Poly Medicure shares surge 3% as Q4 revenue rises 16.6% YoY to Rs 441 crore
By Aman Shukla Published on May 7, 2025, 10:08 IST Poly Medicure Ltd. witnessed a 3% surge in its share price during morning trade following the release of its robust Q4 results. The company reported impressive year-on-year growth across key financial metrics for the quarter. As of 10:06 AM, the shares were trading 3.37% higher at Rs 2,875.00. For Q4, Poly Medicure posted a 16.6% increase in revenue, reaching Rs 441 crore compared to Rs 378 crore in the same period last year. The company's EBITDA saw a notable rise of 23.8%, amounting to Rs 119 crore, up from Rs 96 crore last year. This improvement in profitability was further reflected in the company's EBITDA margin, which expanded to 27%, compared to 25.5% in the previous year. Poly Medicure's net profit also soared by 35.3%, reaching Rs 92 crore as compared to Rs 68 crore in Q4 FY24, demonstrating strong operational efficiency and market demand. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
